- Sales surpass 바카라사이트 캡틴 4.5 trillion, with operating profit margin reaching 45.4%
- Driven by full operation of plants 1-3, higher utilization at Plant 4, and favorable exchange rate effects
[by Ji, Yong Jun] Samsung Biologics, which transitioned to a pure-play contract development and manufacturing organization (CDMO) following its corporate spin-off, reported revenue of KRW 4.5 trillion (approximately USD 3 billion) and operating profit of KRW 2 trillion last year, achieving a robust operating profit margin of 45.4%. This strong performance was driven by the spin-off of Samsung Epis Holdings in November 2025, which restructured the company into a pure CDMO business by excluding the biosimilar operations. Furthermore, Samsung Biologics is projecting earnings growth of approximately 15-20% this year, reinforcing its ‘super gap’ strategy and further consolidating its position as a global CDMO company.
바카라사이트 캡틴 Biologics announced on January 21 that its consolidated revenue for 2025 totaled KRW 4.557 trillion, representing a year-on-year increase of 30.3%. Operating profit for the same period also rose by 56.6% to KRW 2.0692 trillion, while net profit climbed 55.2% to KRW 1.6143 trillion. Notably, the company achieved the upper end of its annual revenue growth forecast (+25-30%) disclosed last year, underscoring its sustained growth momentum and strong business execution capabilities.
The company reported Q4 2025 revenue of 바카라사이트 캡틴 1.2857 trillion, marking a year-on-year increase of more than 35%. Operating profit for the same period reached 바카라사이트 캡틴 528.3 billion, representing an increase of 바카라사이트 캡틴 213.6 billion compared with the prior year and corresponding to a growth rate of 68%.
Notably, Samsung Biologics recorded a landmark performance in operating profitability last year, surpassing KRW 2 trillion in operating profit for the first time in its history. The company’s operating margin reached 45.4% for 2025. Annual operating profit has shown a consistent upward trajectory, increasing from KRW 537.3 billion in 2021 to KRW 1.2042 trillion in 2023, already exceeding the KRW 1 trillion threshold.
The company attributed its strong performance to higher utilization rates at Plant 4, the stable full-scale operation of Plants 1-3, and favorable foreign exchange conditions. Samsung Biologics noted that sustained order growth has been underpinned by its ‘customer-centric management’ philosophy. In 2025, the company secured three large-scale contracts valued at over KRW 1 trillion, bringing total annual orders to more than KRW 6 trillion. Since its founding, Samsung Biologics has accumulated 107 contract manufacturing organization (CMO) contracts and 164 contract development organization (CDO) contracts, with cumulative order value reaching USD 21.2 billion.
Amid increasing global uncertainty stemming from recent changes in the international trade environment and escalating geopolitical tensions, Samsung Biologics has reaffirmed its commitment to sustaining performance growth through a ‘three-axis expansion’ strategy. This approach centered on the continued expansion of production capacity, the strengthening and diversification of its portfolio, and the further strengthening of its global operational footprint.
바카라사이트 캡틴 Biologics has further strengthened its global presence. In the previous year, the company acquired the Rockville facility, making it its first manufacturing site in the United States and establishing a solid foundation for global business expansion. The Rockville plant is equipped with infrastructure capable of supporting a broad range of antibody drug production requirements, spanning clinical development through commercial manufacturing. In addition, 바카라사이트 캡틴 Biologics opened a sales office in Tokyo, Japan, thereby deepening engagement with customers in Japan and Asia while enhancing its responsiveness to regional market demands.
With respect to production capacity expansion, Samsung Biologics has fully commenced operations at Plant 5, with an annual production capacity of 180,000 liters (L). Furthermore, the company installed an additional 1,000-liter bioreactor at Plant 2, increasing total production capacity at its Songdo site (Plants 1-5) to 785,000 liters. When combined with the 60,000-liter capacity of the Rockville facility in the U.S., Samsung Biologics’ total global production capacity is projected to reach approximately 845,000 liters.
In terms of portfolio expansion, Samsung Biologics has taken steps to enhance its competitiveness in next-generation modalities by securing a site for its third Bio Campus in Songdo, Incheon, and finalizing a large-scale investment plan totaling around KRW 7 trillion (approximately 4.7 billion) through 2034. Additionally, with the launch of ‘Samsung Organoid,’ the company is expanding its business scope beyond CDMO services into the contract research organization (CRO) domain, thereby expanding opportunities for collaboration with clients from the early stages of research and development (R&D).
Samsung Biologics expects to sustain strong growth momentum this year, fueled by its enhanced competitiveness under its ‘pure-play CDMO’ strategy, and has guided for year-on-year revenue growth of approximately 15-20%. This forecast excludes any revenue contribution from the recently acquired Rockville facility in the United States. The company indicated that it plans to release additional forecasts reflecting the Rockville site’s performance once the acquisition process has been fully completed.
Conversely, Samsung Biologics reported total assets of KRW 11.06 trillion, shareholders’ equity of KRW 7.45 trillion, and liabilities of KRW 3.60 trillion for 2025. With a debt-to-equity ratio of 48.4% and a debt ratio of 12.3%, the company continues to maintain a sound and stable financial structure.